Real-World Assessment of Relapse, Medical Costs and Persistency of Multiple Sclerosis Patients Treated With Subcutaneous Interferon β-1a. Phillips AL, Locklear JC, Kozma C Value Health. 2015 Nov; 18(7):A755. Epub 2015 Oct 20. PMID: 26534231. Abstract CommentRecommendBookmarkWatch